PE20081897A1 - 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas - Google Patents
3-imidazolil-indoles para el tratamiento de enfermedades proliferativasInfo
- Publication number
- PE20081897A1 PE20081897A1 PE2008000554A PE2008000554A PE20081897A1 PE 20081897 A1 PE20081897 A1 PE 20081897A1 PE 2008000554 A PE2008000554 A PE 2008000554A PE 2008000554 A PE2008000554 A PE 2008000554A PE 20081897 A1 PE20081897 A1 PE 20081897A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- chloro
- halogen
- indol
- imidazol
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- CIEWGZJDEDBECJ-UHFFFAOYSA-N 1-chloro-4-methylbenzene Chemical class [CH2]C1=CC=C(Cl)C=C1 CIEWGZJDEDBECJ-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 ALKENYL (C2-C20) Chemical class 0.000 abstract 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000017274 MDM4 Human genes 0.000 abstract 1
- 108050005300 MDM4 Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3-IMIDAZOLIL-INDOL DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C20), ALQUENILO(C2-C20), ALQUINILO(C2-C20), ARILO(C6-C18), ENTRE OTROS; R2 ES ALQUILO(C1-C20), ALQUENILO(C2-C20), ALQUINILO(C2-C20), HETEROCICLILO DE 3 A 24 MIEMBROS, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO(C1-C20), ALQUINILO(C2-C20), CN, ENTRE OTROS; R4 ES H, HALOGENO, ALQUENILO(C2-C20), CARBOXILO, ENTRE OTROS; RA ES H, ALQUILO(C1-C20) O ACILO; X ES H, ALQUILO(C1-C7), HALOALQUILO(C1-C7), HALOGENO, ENTRE OTROS; Y ES ALQUILO(C1-C7), ALCOXILO(C1-C7), HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL, (2-MORFOLIN-4-IL-ETIL)-AMIDA DEL ACIDO 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL-2-CARBOXILICO, ETIL-ESTER DEL ACIDO 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL-2-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA INTERACCION ENTRE P53 O VARIANTES DE LA MISMA CON EL ONCOGEN DIMINUTO DOBLE DE MURINO MDM2 O MDM4 SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, LUPUS ERITEMATOSO SISTEMICO, ESCLEROSIS MULTIPLE, ASMA, OSTEOSARCOMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105269 | 2007-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081897A1 true PE20081897A1 (es) | 2009-02-09 |
Family
ID=38328915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000554A PE20081897A1 (es) | 2007-03-29 | 2008-03-27 | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8053457B2 (es) |
| EP (1) | EP2142535A2 (es) |
| JP (1) | JP2010522723A (es) |
| KR (1) | KR20090122403A (es) |
| CN (1) | CN101679382A (es) |
| AR (1) | AR065860A1 (es) |
| AU (1) | AU2008234954B9 (es) |
| BR (1) | BRPI0810082A2 (es) |
| CA (1) | CA2682483A1 (es) |
| CL (1) | CL2008000899A1 (es) |
| CR (1) | CR11019A (es) |
| DO (1) | DOP2009000229A (es) |
| EA (1) | EA200901212A1 (es) |
| EC (1) | ECSP099660A (es) |
| GT (1) | GT200900256A (es) |
| IL (1) | IL200862A0 (es) |
| MA (1) | MA31260B1 (es) |
| MX (1) | MX2009010413A (es) |
| NI (1) | NI200900177A (es) |
| PA (1) | PA8774001A1 (es) |
| PE (1) | PE20081897A1 (es) |
| SM (1) | SMP200900085B (es) |
| TN (1) | TN2009000388A1 (es) |
| TW (1) | TW200843746A (es) |
| UY (1) | UY30987A1 (es) |
| WO (1) | WO2008119741A2 (es) |
| ZA (1) | ZA200906210B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5132673B2 (ja) * | 2006-04-07 | 2013-01-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| WO2009158375A1 (en) * | 2008-06-25 | 2009-12-30 | Abbott Laboratories | Aza-cylic indole- 2 -carboxamides and methods of use thereof |
| KR101734955B1 (ko) | 2008-11-07 | 2017-05-12 | 메사추세츠 인스티튜트 오브 테크놀로지 | 아미노알콜 리피도이드 및 그의 용도 |
| PL2380892T3 (pl) * | 2009-01-16 | 2014-08-29 | Daiichi Sankyo Co Ltd | Pochodna imidazotiazolowa mająca strukturę pierścienia proliny |
| JP2012102017A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | インドール化合物 |
| WO2010119984A1 (en) * | 2009-04-16 | 2010-10-21 | Banyu Pharmaceutical Co.,Ltd. | 3-aryl or heteroaryl-substituted indole derivative |
| PH12012500870A1 (en) | 2009-11-12 | 2012-11-26 | Univ Michigan Regents | Spiro-oxindole mdm2 antagonists |
| WO2011106650A2 (en) * | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| AU2011299551A1 (en) | 2010-09-08 | 2013-03-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | P53-Mdm2 antagonists |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| PE20140408A1 (es) | 2010-11-12 | 2014-04-10 | Univ Michigan | Derivados espiro-oxindol como antagonistas de mdm2 |
| US20120202794A1 (en) * | 2011-01-24 | 2012-08-09 | Pharmasset, Inc. | Compounds |
| CA2829188C (en) | 2011-03-10 | 2016-10-18 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
| EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
| CN102702066A (zh) * | 2011-03-28 | 2012-10-03 | 苏州百灵威超精细材料有限公司 | 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法 |
| EP2707372B1 (en) | 2011-05-11 | 2016-12-21 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| WO2012176123A1 (en) * | 2011-06-22 | 2012-12-27 | Novartis Ag | 3 - imidazolyl- indoles for the treatment of proliferative diseases |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| MX2014007093A (es) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Metodos para mejorar terapias medicas. |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| EP3669881B1 (en) | 2014-01-28 | 2022-03-30 | Buck Institute for Research on Aging | Compositions for use in the treatment of senescence-assiocated eye disease and disorders |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| EP3164401B1 (en) | 2014-07-03 | 2018-12-26 | Boehringer Ingelheim International GmbH | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| DK3183254T3 (da) | 2014-08-21 | 2019-08-19 | Boehringer Ingelheim Int | Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer |
| US20180006236A1 (en) | 2014-12-26 | 2018-01-04 | Dow Global Technologies Llc | Organic compounds and electronic device comprising organic layer comprising organic compounds |
| TWI711452B (zh) | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | 癌症的倂用治療法 |
| US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
| JP6971858B2 (ja) * | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2017060431A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| CN109311900A (zh) | 2016-04-06 | 2019-02-05 | 密执安大学评议会 | 用于配体依赖性靶蛋白质降解的单官能中间体 |
| CA3020275A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Mdm2 protein degraders |
| US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
| CN105906610B (zh) * | 2016-05-24 | 2018-10-23 | 绍兴文理学院 | 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用 |
| HUE045355T2 (hu) * | 2016-07-21 | 2019-12-30 | Inst Farmakologii Polskiej Akademii Nauk | Az 5-HT7 szerotoninreceptort kötõ imidazolil-szubsztituált indolszármazékok és gyógyszerészeti készítményeik |
| CN109843329A (zh) | 2016-10-17 | 2019-06-04 | 第一三共株式会社 | 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法 |
| WO2018096159A1 (en) | 2016-11-28 | 2018-05-31 | F. Hoffmann-La Roche Ag | Oxadiazolones as transient receptor potential channel inhibitors |
| IL291308B2 (en) | 2016-12-21 | 2024-07-01 | Bayer Pharma AG | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
| CN110461838B (zh) | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
| CN110505884B (zh) | 2017-04-05 | 2022-08-12 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| WO2018218192A1 (en) * | 2017-05-26 | 2018-11-29 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| US12118414B2 (en) | 2018-01-22 | 2024-10-15 | Bioventures, Llc | BCL-2 proteins degraders for cancer treatment |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| US12281099B2 (en) * | 2019-02-26 | 2025-04-22 | Boehringer Ingelheim International Gmbh | Isoindolinone substituted indoles and derivatives as RAS inhibitors |
| WO2020176983A1 (en) | 2019-03-01 | 2020-09-10 | Ontario Institute For Cancer Research (Oicr) | Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses |
| PE20240229A1 (es) * | 2020-12-22 | 2024-02-16 | Novartis Ag | DERIVADOS DE INDOL UTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS |
| WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| CN117510416A (zh) * | 2023-11-06 | 2024-02-06 | 浙江普洛康裕制药有限公司 | 一种(2R,5S)-4-Boc-2,5-二甲基哌嗪的制备方法 |
| PL447976A1 (pl) * | 2024-03-11 | 2025-09-15 | Celon Pharma Spółka Akcyjna | Pochodna imidazolo-indolowa wiążąca się z receptorem serotoninowym 5-HT7, kompozycja farmaceutyczna zawierająca tę pochodną, zastosowania pochodnej i kompozycji oraz produkt pośredni do wytwarzania pochodnej imidazolo-indolowej |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19948417A1 (de) * | 1999-10-07 | 2001-04-19 | Morphochem Ag | Imidazol-Derivate und ihre Verwendung als Arzneimittel |
| JP2002114780A (ja) * | 2000-10-11 | 2002-04-16 | Taisho Pharmaceut Co Ltd | ４−（３−インドリル）イミダゾール誘導体 |
| MX2007010272A (es) | 2005-02-22 | 2008-03-12 | Univ Michigan | Inhibidores de moleculas pequenas de mdm2 y usos de los mismos. |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
-
2008
- 2008-03-27 WO PCT/EP2008/053667 patent/WO2008119741A2/en not_active Ceased
- 2008-03-27 AR ARP080101262A patent/AR065860A1/es unknown
- 2008-03-27 CN CN200880017611A patent/CN101679382A/zh active Pending
- 2008-03-27 EP EP08735532A patent/EP2142535A2/en not_active Withdrawn
- 2008-03-27 BR BRPI0810082-9A2A patent/BRPI0810082A2/pt not_active IP Right Cessation
- 2008-03-27 KR KR1020097022526A patent/KR20090122403A/ko not_active Withdrawn
- 2008-03-27 PE PE2008000554A patent/PE20081897A1/es not_active Application Discontinuation
- 2008-03-27 CA CA002682483A patent/CA2682483A1/en not_active Abandoned
- 2008-03-27 EA EA200901212A patent/EA200901212A1/ru unknown
- 2008-03-27 MX MX2009010413A patent/MX2009010413A/es not_active Application Discontinuation
- 2008-03-27 JP JP2010500280A patent/JP2010522723A/ja active Pending
- 2008-03-27 AU AU2008234954A patent/AU2008234954B9/en not_active Ceased
- 2008-03-27 US US12/593,721 patent/US8053457B2/en not_active Expired - Fee Related
- 2008-03-28 PA PA20088774001A patent/PA8774001A1/es unknown
- 2008-03-28 TW TW097111568A patent/TW200843746A/zh unknown
- 2008-03-28 CL CL2008000899A patent/CL2008000899A1/es unknown
- 2008-03-28 UY UY30987A patent/UY30987A1/es not_active Application Discontinuation
-
2009
- 2009-09-08 ZA ZA200906210A patent/ZA200906210B/xx unknown
- 2009-09-09 CR CR11019A patent/CR11019A/es unknown
- 2009-09-10 IL IL200862A patent/IL200862A0/en unknown
- 2009-09-24 MA MA32230A patent/MA31260B1/fr unknown
- 2009-09-24 TN TNP2009000388A patent/TN2009000388A1/fr unknown
- 2009-09-28 NI NI200900177A patent/NI200900177A/es unknown
- 2009-09-28 GT GT200900256A patent/GT200900256A/es unknown
- 2009-09-28 DO DO2009000229A patent/DOP2009000229A/es unknown
- 2009-09-29 EC EC2009009660A patent/ECSP099660A/es unknown
- 2009-10-28 SM SM200900085T patent/SMP200900085B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR065860A1 (es) | 2009-07-08 |
| CN101679382A (zh) | 2010-03-24 |
| WO2008119741A3 (en) | 2008-12-04 |
| PA8774001A1 (es) | 2008-11-19 |
| MX2009010413A (es) | 2009-10-20 |
| TN2009000388A1 (en) | 2010-12-31 |
| US20100125064A1 (en) | 2010-05-20 |
| KR20090122403A (ko) | 2009-11-27 |
| ECSP099660A (es) | 2009-10-30 |
| AU2008234954B2 (en) | 2011-10-27 |
| WO2008119741A2 (en) | 2008-10-09 |
| US8053457B2 (en) | 2011-11-08 |
| CR11019A (es) | 2009-10-20 |
| GT200900256A (es) | 2010-03-15 |
| DOP2009000229A (es) | 2009-10-31 |
| JP2010522723A (ja) | 2010-07-08 |
| BRPI0810082A2 (pt) | 2014-10-21 |
| EP2142535A2 (en) | 2010-01-13 |
| MA31260B1 (fr) | 2010-03-01 |
| AU2008234954B9 (en) | 2012-02-02 |
| AU2008234954A1 (en) | 2008-10-09 |
| CL2008000899A1 (es) | 2009-02-20 |
| UY30987A1 (es) | 2008-10-31 |
| SMP200900085B (it) | 2010-11-12 |
| TW200843746A (en) | 2008-11-16 |
| ZA200906210B (en) | 2010-05-26 |
| NI200900177A (es) | 2010-09-09 |
| EA200901212A1 (ru) | 2010-04-30 |
| CA2682483A1 (en) | 2008-10-09 |
| SMAP200900085A (it) | 2010-01-19 |
| IL200862A0 (en) | 2010-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081897A1 (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
| PE20131197A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen | |
| PE20142019A1 (es) | Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40 | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| RU2434853C2 (ru) | Новые конденсированные производные пиррола | |
| PE20090157A1 (es) | Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119) | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| CY1107244T1 (el) | Μιμητικα γλυκοκορτικοειδων, μεθοδοι παρασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
| PE20070419A1 (es) | Derivados de benzoquinazolina | |
| PE20120691A1 (es) | Derivados de n1-sulfonil-5-fluoropirimidinona | |
| PE20110368A1 (es) | Moduladores de mif | |
| PE20161443A1 (es) | Compuestos | |
| CY1111702T1 (el) | Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1 | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20130158A1 (es) | Inhibidores no nucleosidicos de la transcriptasa inversa | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| PE20130281A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
| PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
| AR070797A1 (es) | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
| PE20140610A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |